At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Bortezomib +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Etoposide, and 5 other interventions for Leukemia-Lymphoma, Adult T-Cell. Completed, enrolled 18 participants across 6 sites.
Detailed Summary
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus replication and expression, and tumor cell proliferation to gain understanding of the biological basis of this malignancy and to identify predictors of response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia-Lymphoma, Adult T-Cell
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartSep 2010
Primary CompletionMay 2014
Study CompletionApr 2016
TodayJul 2026
First PostedOct 23, 2009
Enrollment StartSep 1, 2010
Primary CompletionMay 1, 2014
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.7 years ago
Interventions
Bortezomibdrug
Etoposidedrug
Vincristinedrug
Doxorubicindrug
Prednisonedrug
Cyclophosphamidedrug
Raltegravirdrug